Toru Mukohara

13PUBLICATIONS
77CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Jul 07, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

|Jan 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano

|Apr 02, 2025
Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer.

Mao Uematsu, Hiromichi Nakajima, Hirohiko Miyake

|Mar 27, 2025
The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer.

Shu Kato, Kaede Baba, Kanako Mamishin

Pageof 3

Frequent Collaborators

4 joint publications

Yoichi Naito

4 joint publications

Nobuaki Matsubara

2 joint publications

Nobuyuki Takahashi

2 joint publications

Toshikatsu Kawasaki